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Summary Invasive aspergillosis remains associated with significant morbidity and mortality,
necessitating new options for salvage therapy. The objective of this study was to
evaluate the efficacy and safety of micafungin as salvage monotherapy in patients
with invasive aspergillosis. Patients with proven or probable invasive aspergillosis,
who were refractory or intolerant to previous systemic antifungal therapy, were
randomised 2 : 1 to receive 300 mg day1 intravenous micafungin monotherapy or
an intravenous control monotherapy [lipid amphotericin B (5 mg kg1 day1),
voriconazole (8 mg kg1 day1) or caspofungin (50 mg day1)] for 3–12 weeks.
Patients underwent final assessment 12 weeks after treatment start. Seventeen
patients with invasive aspergillosis (proven, n = 2; probable, n = 14; not recorded,
n = 1) participated in the study (micafungin arm, n = 12; control arm, n = 5). Three
patients each in the micafungin (25.0%; 95% CI: 5.5–57.2) and control arm
(60.0%; 95% CI: 14.7–94.7) had successful therapy at end of treatment as assessed
by an Independent Data Review Board. Eleven patients died; six due to invasive
aspergillosis. No deaths were considered related to study treatment. During this study
it became increasingly common to use combination treatment for salvage therapy.
Consequently, enrolment was low and the study was discontinued early. No clear
trends in efficacy and safety can be concluded.
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Introduction
Invasive aspergillosis is still associated with significant
morbidity and mortality rates.1–6 Immunocompro-
mised patients, such as those receiving cancer chemo-
therapy, immunosuppressive drug regimens, allogeneic
haematopoietic stem cell and solid organ transplanta-
tions, and those with immunologic diseases, are partic-
ularly at risk of developing life-threatening systemic
fungal infections caused by Aspergillus spp. As progno-
sis may be worse if first-line therapy fails or is not tol-
erated, new options for salvage therapy are warranted.
Historically, treatment of invasive aspergillosis has
consisted of three general pharmacologic approaches,
each with their own limitations. For decades ampho-
tericin B deoxycholate (later followed by liposomal,
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colloidal dispersion and lipid complex formulations)
was considered the standard treatment for invasive
aspergillosis.7 The lipid-based formulations have an
improved safety profile; however, this agent remains
associated with toxic effects and suboptimal response
rates.8–11
Voriconazole was the first promising alternative to
amphotericin B,12,13 and is currently recommended as
first-line therapy for invasive aspergillosis.14 Survival
rates with voriconazole (~71%) are significantly higher
compared with amphotericin B deoxycholate (~58%);
however, triazoles are associated with hepatotoxicity
and drug–drug interactions.13,15 The echinocandins,
anidulafungin, caspofungin and micafungin, are gen-
erally well tolerated, and few significant drug interac-
tions have been reported.14
For salvage therapy, recommended agents include
lipid-based formulations of amphotericin B; the triazoles,
posaconazole and itraconazole; and the echinocandins,
caspofungin and micafungin.7 Current guidelines rec-
ommend a change in class to amphotericin B or an echi-
nocandin for salvage therapy.14 However, it is also
recognised that due to their distinct mechanisms of
action and compatible safety profiles, combinations of
agents from these different classes may be deployed.
Micafungin is an echinocandin which has broad-
spectrum activity, including fungicidal activity against
Candida spp. and fungistatic activity against Aspergillus
spp.16 The aim of the current study was to evaluate
the efficacy and safety of micafungin as salvage mono-
therapy in patients with proven or probable invasive
aspergillosis who were refractory or intolerant to pre-
vious systemic antifungal therapy. The efficacy and
safety of micafungin monotherapy, as compared with
standard monotherapy, were also examined. The study
was initiated in June 2006; however, after more than
2 years it was discontinued prematurely, having
screened 301 patients, due to slow enrolment in asso-
ciation with a change in preference from monotherapy
to combination therapy for salvage of invasive
aspergillosis.
Patients and methods
This was a Phase II, multicentre, prospective, con-
trolled, open-label, randomised and parallel arm clini-
cal study (NCT00376337), conducted between 30
June 2006 and 7 September 2008. Patients were
randomised 2 : 1 to receive either 300 mg once-daily
(QD) intravenous micafungin monotherapy or an
alternative intravenous control salvage monotherapy
[amphotericin B liposomal (5 mg kg1 QD), colloidal
dispersion (5 mg kg1 QD) or lipid complex
(5 mg kg1 QD); voriconazole (6 mg kg1 twice daily
loading dose followed by 4 mg kg1 twice daily); or
caspofungin (70 mg loading dose followed by 50 mg
QD)] for a period of 3–12 weeks. Patients underwent
their final assessment 12 weeks after the start of
treatment.
Patients aged ≥18 years old were eligible for inclu-
sion if they had proven invasive aspergillosis (probable
in cases of pulmonary infection), an allogeneic or autol-
ogous haematopoietic stem cell transplant, acute leu-
kaemia or myelodysplastic syndrome, and were
refractory to a systemic antifungal agent used as first-
line therapy, or intolerant to at least one dose of a
systemic antifungal agent used as first-line therapy.
Refractory patients were defined as those who had
received at least seven consecutive days of systemic
antifungal therapy prior to the start of the study and
who had progression of infection (i.e. rapid worsening
of clinical conditions and evidence either of new lesions
or dissemination of disease with the occurrence of cere-
bral, cutaneous or hepatosplenic abscesses) or failure to
improve [i.e. persistence of fever and lack of significant
reduction (≥50%) of the number or size of known
lesions]. Evidence of intolerability included doubling of
serum creatinine levels within 48 h, serum creatinine
≥2.0 mg dl1, persistence of severe visual disturbance,
acute hepatotoxicity or other significant drug-related
toxicity which precluded continuation of treatment, e.g.
allergic reaction or severe infusion reaction.
The primary efficacy endpoint was the overall treat-
ment success at end of treatment (EOT), defined as com-
plete or partial clinical response, i.e. resolution of all
(complete), or major improvement or resolution (par-
tial) of clinical signs and symptoms (e.g. respiratory and
neurological) attributable to invasive aspergillosis, and
at least a 90% (complete) or at least 50% (partial)
improvement in radiological signs compared to baseline.
The secondary endpoint was the overall treatment
success at 12 weeks after the start of treatment.
Statistical analyses
The original study protocol had a priori defined exten-
sive analysis of study data based on a projected enrol-
ment of 135 patients (micafungin arm: n = 90 vs.
control arm: n = 45), including analysis of primary
and secondary outcomes. However, as a consequence
of the premature discontinuation of the study and the
resulting low number of patients randomised, only
descriptive statistical analysis and calculation of 95%
confidence intervals were performed for efficacy
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endpoints based on the full analysis set (FAS; defined
as all randomised patients who received at least one
dose of study medication). Statistical comparisons
between treatment arms were not conducted. Safety
data including incidence of adverse events (AEs), seri-
ous AEs and deaths were described, but not further
analysed.
Independent Data Review Board assessments
An Independent Data Review Board (IDRB) of clinical
experts assessed the clinical data for all patients
enrolled and included in the FAS. The IDRB assessed
the fungal infection status at baseline, clinical signs
and symptoms, radiological findings, clinical and
mycological responses and overall success at 12 weeks
after the start of treatment and at EOT, as well as the
relationship of mortality to fungal infection and under-
lying disease. A radiologist was consulted for inter-
pretation of the radiological results. The IDRB was
treatment-blinded, i.e. enabled to see neither details
regarding the systemic antifungal agents administered
nor any other information that could have revealed
the actual treatment used as study medication.
Results
In total, 301 patients were prescreened at 64 sites in
12 countries; however, only 17 (5.6%) were enrolled
to this study as the majority of patients screened
received combination therapy rather than monothera-
py. Patients were enrolled from nine out of the 64 par-
ticipating sites in eight countries (Fig. 1).
Twelve patients were randomised to the micafungin
treatment arm and five patients were randomised to the
control arm (Fig. 2). Of these, seven patients completed
study treatment and four patients completed the study.
Patient characteristics
The majority of patients were male (n = 11; 64.7%)
and Caucasian (n = 15; 88.2%). Mean patient age was
53.6 years (range 25–76 years), mean body weight
was 68.5 kg (range 45–85 kg) and mean height was
173.3 cm (range 157–191 cm). Nine patients had
neutropenia and five patients had received an alloge-
neic stem cell transplant. Primary underlying diseases
were acute lymphocytic leukaemia (n = 1; 5.9%),
acute myelogenous leukaemia (n = 12; 70.6%), myelo-
dysplastic syndrome (n = 1; 5.9%) and other (n = 3;
17.6%). The status of underlying diseases at the start
of the study was: active (n = 9; 52.9%), remission
(n = 3; 17.6%) and relapse (n = 5; 29.4%). The
therapies given for primary underlying diseases were
haematopoietic stem cell transplant (n = 5; 29.4%, all
in the micafungin arm), prolonged corticosteroid
therapy (n = 3; 17.6%, all in the micafungin arm) and
chemotherapy (n = 9; 52.9%, six in the micafungin
arm).
Invasive aspergillosis status
Invasive fungal infection was proven in two patients,
probable in 14 patients and not recorded in one
patient. The lung was the main site of infection in all
patients. Invasive aspergillosis was most frequently
diagnosed using computed tomography (n = 15;
88.2%). In addition, 12 out of 16 patients (75.0%)
who underwent galactomannan testing had a positive
result. One patient, who did not receive a computed
tomography scan, was diagnosed with probable inva-
sive aspergillosis based on X-ray evidence of a new
infiltrate, a positive galactomannan test result and
symptoms of lower respiratory tract infection (includ-
ing cough).
The following organisms were identified in the
micafungin/control arms (n/n): Aspergillus fumigatus
(n/n = 1/1); Aspergillus flavus (n/n = 1/0); unidentified
Aspergillus spp. (n/n = 9/4); other mould, not other-
wise specified (n/n = 1/0). Of the 13 patients with
an unidentified Aspergillus spp. infection, 10 (n/
n = 6/4) had a positive galactomannan antigen test
result.
First-line and study treatments for invasive
aspergillosis
All patients had received treatment with a systemic
antifungal medication prior to the first dose of study
medication. Six patients had received antifungal
Figure 1 Number of prescreened and randomised patients by
month from June 2006 to September 2008.
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prophylaxis with either fluconazole (n = 2; 11.8%),
itraconazole (n = 2: 11.8%) or amphotericin B (n = 2;
11.8%). Drugs administered as first-line therapies were
voriconazole (n = 11; 64.7%) and amphotericin B for-
mulations (n = 6; 35.3%). Fifteen patients (88.2%)
were considered refractory to first-line therapy (nine
for progression of infection and six for failure to
improve) and two (11.8%) were intolerant to first-line
therapy. Twelve patients (70.6%) were randomised to
receive salvage therapy with micafungin and five
patients (29.4%) were randomised to the control arm.
Salvage therapies administered in the control arm
were caspofungin (n = 4) and voriconazole (n = 1). No
patients received amphotericin B salvage
monotherapy.
The median study treatment duration was 10 days
(range 4–34 days) in the micafungin treatment arm
and 18 days (range 10–64 days) for the control arm.
Reasons for discontinuation of treatment in the
micafungin arm included: completed therapy (n = 2;
Days 24 and 26), lack of efficacy (n = 4; Days 8, 10,
10, and 34), AEs (n = 2; Days 4 and 25) and other
(n = 4; Days 5, 7, 8, and 29). In the control arm,
reasons for treatment discontinuation included com-
pleted therapy (n = 2; Days 34 and 64), AEs (n = 1;
Day 11) and other (n = 2; Days 10 and 18). Study
duration varied between 5 and 119 days after
randomisation.
Efficacy
Three patients in the micafungin treatment arm
(25.0%; 95% CI: 5.5–57.2) and three patients in the
control arm (60.0%; 95% CI: 14.7–94.7) had success-
ful therapy at EOT (Table 1). Six patients in the
micafungin treatment arm (50.0%; 95% CI: 21.1–
78.9) and one patient in the control arm (20.0%; 95%
CI: 0.5–71.6) had successful therapy at 12 weeks after
the start of treatment (Table 1).
Safety
Eleven patients died during the study: five during
treatment [three in the micafungin arm (25.0%) and
two in the control arm (40.0%)] and six in the post-
treatment period [four in the micafungin arm (33.3%)
and two in the control arm (40.0%)] (Fig. 2). Six
patients’ deaths were considered to be attributable to
invasive aspergillosis by the IDRB [four in the mica-
fungin arm (33.3%) and two in the control arm
Table 1 Overall treatment success at the end of treatment and
at 12 weeks after the start of treatment.
Micafungin (n = 12) Control (n = 5)
Primary endpoint
FAS at EOT
Successful therapy, n (%) 3 (25.0) 3 (60.0)
95% CI 5.5–57.2 14.7–94.7
Secondary endpoint
FAS at 12 weeks after the start of treatment
Successful therapy, n (%) 6 (50.0) 1 (20.0)
95% CI 21.1–78.9 0.5–71.6
Not recorded, n (%) 6 (50.0) 4 (80.0)
FAS, full analysis set; CI, confidence interval; EOT, end of
treatment.
Figure 2 Disposition of patients.
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(40.0%)]. Infections, and events within the system
organ classes ‘respiratory’, ‘blood’, and ‘general disor-
ders’ were the causes of death. No deaths were consid-
ered related to study treatments.
Fifteen patients (88.2%) experienced AEs in this
study (Table 2). AEs reported by two or more patients
per treatment arm were leucocytosis, neutropenia,
melaena, nausea, chest pain and sepsis. Three patients
in the micafungin arm experienced AEs of nausea
(n = 1; 8.3%), vomiting (n = 1; 8.3%), diarrhoea
(n = 1; 8.3%) and hyperbilirubinaemia (n = 1; 8.3%),
which were considered related to micafungin treat-
ment. One patient (20.0%) in the control arm experi-
enced a serious AE of cholestasis, which was
considered related to caspofungin treatment.
Discussion
This study was conducted to evaluate the efficacy and
safety of micafungin as salvage monotherapy in
patients with proven or probable invasive aspergillosis
who were refractory or intolerant to previous systemic
antifungal therapy. At the time of the study, prefer-
ences for salvage treatment of invasive aspergillosis
evolved to largely preclude the use of monotherapy.
Over time, this evolution increasingly conflicted with
the study design, which required monotherapy at
baseline. This led to low enrolment (N = 17, where
N = 120 was originally intended) in 28 months and
the study was discontinued prematurely.
Seventeen patients were randomised to receive either
micafungin monotherapy or monotherapy with a con-
trol, i.e. caspofungin or voriconazole. Of the 17 patients,
15 received a diagnosis of invasive aspergillosis using
computed tomography imaging and 10 had a positive
galactomannan antigen test result. Salvage therapy in
three out of the 12 patients in the micafungin treatment
arm and three out of the five patients in the control arm
was rated as successful at EOT by the IDRB. Eleven
patients died during the study, which was not unex-
pected, given the high number of active and relapsed
malignancies in this patient population. In addition, the
majority of patients were neutropenic and five had
received an allogeneic stem cell transplant, which are
known predictors of mortality in invasive aspergillo-
sis.17 Infections, respiratory, blood and general disorders
were identified as the causes of death. No new safety
issues were identified in invasive aspergillosis patients
who were administered micafungin. Due to the small,
heterogeneous patient population and imbalance in
patient numbers between treatment arms, no clear
trends in efficacy could be concluded.
Treatment of invasive aspergillosis was traditionally
initiated as monotherapy. However, although thera-
peutic responses in invasive aspergillosis have generally
improved with newer treatments, outcomes remain dis-
appointing, particularly in high-risk patients such as
those patients undergoing allogeneic haematopoietic
stem cell transplant.13,18,19 In order to improve thera-
peutic outcomes, researchers have explored a number
of different combinations of antifungal agents.20 Regi-
mens which partner lipid-based amphotericin B formu-
lations or a triazole with an echinocandin are
particularly attractive due to their distinct mechanisms
of action and complementary safety profiles.
In a recent subgroup analysis of patients enrolled in
the Prospective Antifungal Therapy Alliance registry,
approximately 29% of patients with invasive aspergil-
losis received combination therapy as initial treat-
ment.21 The most commonly administered
combination was voriconazole plus an echinocandin;
however, 56 unique combinations of two or more
antifungal agents were recorded in this cohort of
patients during the 12-week follow-up period. Similar
findings have also been reported by the Transplant
Associated Infection Surveillance Network.22
Despite the growing employment of combination
therapy, there have been few prospective studies con-
ducted to examine its utility and evidence supporting
its use in clinical practice is often conflicted.23 For
example, in an early retrospective cohort study, Kon-
toyiannis et al. [20] found that combination liposomal
amphotericin B plus caspofungin may be useful as pre-
emptive therapy for invasive aspergillosis and may
have limited benefit as salvage therapy. Moreover, a
subsequent randomised, prospective, pilot trial also
found that combination therapy with these agents
yielded significantly more favourable responses than





















AE 10 (83.3) 36 5 (100.0) 29 15 (88.2) 65
SAE 5 (41.7) 7 4 (80.0) 8 9 (52.9) 15
Causally
related AE
3 (25.0) 4 1 (20.0) 1 4 (23.5) 5
Causally
related SAE
0 0 1 (20.0) 1 1 (5.9) 1
Causally related: defined as probable, possible or missing relation-
ship with study drug as assessed by investigator.
AE, adverse event; SAE, serious adverse event.
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monotherapy with liposomal amphotericin B.24 By con-
trast, two retrospective cohort studies demonstrated
that combination therapy with lipid-based amphoteri-
cin B plus an echinocandin offers no therapeutic
advantage in salvage therapy compared with mono-
therapy using either posaconazole25 or an echinocan-
din alone.26 Studies of other combinations, such as
voriconazole plus caspofungin, yielded similarly incon-
clusive results.27–29
Notwithstanding the lack of prospective clinical trial
evidence, current clinical guidelines developed by the
Infectious Diseases Society of America recognise that ‘in
the context of salvage therapy, an additional antifungal
agent might be added to current therapy, or combination
antifungal drugs from different classes other than those in
the initial regimen may be used’.7 Appropriate salvage
therapy for invasive aspergillosis remains a major clinical
challenge. Clearly, the potential for combination therapy
in these patient populations merits further prospective,
randomised clinical studies to compare newer treatment
strategies and different combinations of agents.
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